Serina Therapeutics Inc.
SER
Get informed when a big investor buys or sells
+ FollowMarket Cap$30M
Close$
$0.28
84.1% downside
Current Fair Value
84.1% downsideOvervalued by 84.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $30.00 Million |
|---|---|
| Enterprise Value | $7.09 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.91 |
| Beta | 0.03 |
| Outstanding Shares | 16,385,000 |
Return
| Return on Equity | -114.61% |
|---|---|
| Return on Assets | -83.16% |
| Return on Invested Capital | -90.94% |
Valuation & Multiples
| P/E Ratio | -1.06 |
|---|---|
| PEG | 74.56 |
| Price to Sales | - |
| Price to Book Ratio | 1.77 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.35 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.49
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.58%▼ 3.64% |
|---|---|
| Total Invested | $2.73M▼ 4.50% |
| Investors Holding | 27▲ 2.00% |
ESG Score
No data
About Serina Therapeutics Inc.
12 employees
CEO: Michael West agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic cand...